{
    "id": 2994,
    "name": "germ cell cancer",
    "source": "DOID",
    "definition": "A cell type cancer that has_material_basis_in abnormally proliferating cells derives_from germ cells. [url:http\\://en.wikipedia.org/wiki/Germ_cell_tumor]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        "2157"
    ],
    "termId": "DOID:2994",
    "evidence": [
        {
            "id": 672,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a small Phase II study, 18 patients with KIT-positive refractory germ cell tumors treated with Gleevec (imatinib) experienced no significant antitumor activity (PMID: 16462496).",
            "molecularProfile": {
                "id": 851,
                "profileName": "KIT positive"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2994,
                "name": "germ cell cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 390,
                    "pubMedId": 16462496,
                    "title": "Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16462496"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11225,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Votrient (pazopanib) treatment resulted in partial responses in 4.7% (2/43), stable disease in 44.2% (19/43), and a 3-month progression free survival probability of 12.8% in patients with refractory germ cell cancer (PMID: 28383677).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 848,
                "therapyName": "Pazopanib",
                "synonyms": null
            },
            "indication": {
                "id": 2994,
                "name": "germ cell cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9174,
                    "pubMedId": 28383677,
                    "title": "Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28383677"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12690,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with germ cell cancer demonstrated stable disease for greater than 6 months when treated with Ipafricept (OMP-54F28) (PMID: 28954784).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2396,
                "therapyName": "Ipafricept",
                "synonyms": null
            },
            "indication": {
                "id": 2994,
                "name": "germ cell cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10602,
                    "pubMedId": 28954784,
                    "title": "A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28954784"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT00936936",
            "title": "High-dose Chemotherapy for Poor-prognosis Relapsed Germ-Cell Tumors",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 755,
                    "therapyName": "Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 1441,
                    "therapyName": "Ifosfamide",
                    "synonyms": null
                },
                {
                    "id": 1136,
                    "therapyName": "Etoposide",
                    "synonyms": null
                },
                {
                    "id": 1207,
                    "therapyName": "Melphalan",
                    "synonyms": null
                },
                {
                    "id": 2101,
                    "therapyName": "Etoposide + Ifosfamide",
                    "synonyms": null
                },
                {
                    "id": 2100,
                    "therapyName": "Docetaxel + Gemcitabine + Melphalan",
                    "synonyms": null
                },
                {
                    "id": 2074,
                    "therapyName": "Bevacizumab + Carboplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00983398",
            "title": "Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 1476,
                    "therapyName": "Pegfilgrastim",
                    "synonyms": null
                },
                {
                    "id": 1632,
                    "therapyName": "Filgrastim",
                    "synonyms": null
                },
                {
                    "id": 2587,
                    "therapyName": "Carboplatin + Melphalan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01037790",
            "title": "PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 850,
                    "therapyName": "Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01331135",
            "title": "Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 917,
                    "therapyName": "Sirolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01625351",
            "title": "A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1166,
                    "therapyName": "Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 1207,
                    "therapyName": "Melphalan",
                    "synonyms": null
                },
                {
                    "id": 1206,
                    "therapyName": "Busulfan",
                    "synonyms": null
                },
                {
                    "id": 1205,
                    "therapyName": "Alemtuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01962896",
            "title": "A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2253,
                    "therapyName": "Erlotinib + Sirolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02034110",
            "title": "Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02130869",
            "title": "A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2378,
                    "therapyName": "Bendamustine + Cytarabine + Etoposide",
                    "synonyms": null
                },
                {
                    "id": 2460,
                    "therapyName": "Busulfan + Hu14.18K322A",
                    "synonyms": null
                },
                {
                    "id": 2459,
                    "therapyName": "Aldesleukin + Melphalan + Sargramostim",
                    "synonyms": null
                },
                {
                    "id": 1632,
                    "therapyName": "Filgrastim",
                    "synonyms": null
                },
                {
                    "id": 1791,
                    "therapyName": "Carboplatin + Etoposide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02300987",
            "title": "A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent Progression",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 790,
                    "therapyName": "Ribociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02429466",
            "title": "Study of the Hypomethylating Drug SGI-110 Plus Cisplatin in Relapsed Refractory Germ Cell Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 1949,
                    "therapyName": "Guadecitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02454972",
            "title": "Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1195,
                    "therapyName": "Lurbinectedin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02499952",
            "title": "Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02839694",
            "title": "Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 3567,
                    "therapyName": "Decitabine + Tetrahydrouridine",
                    "synonyms": null
                },
                {
                    "id": 4592,
                    "therapyName": "Celecoxib + Decitabine + Tetrahydrouridine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02988843",
            "title": "Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors",
            "phase": "Phase II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 5144,
                    "therapyName": "Bevacizumab + Brentuximab vedotin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03158064",
            "title": "Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2439,
                    "therapyName": "Durvalumab + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03333616",
            "title": "Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03698994",
            "title": "Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 997,
                    "therapyName": "Ulixertinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03760081",
            "title": "A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9742,
                    "therapyName": "ASP1650",
                    "synonyms": null
                }
            ]
        }
    ]
}